According to the science and Technology Daily on the 13th, on May 10, the new crown treatment drug discovered by Chinese scientists was authorized by the national invention patent. The patent specification shows that 10um (micromol / L) stephanine inhibits coronavirus replication by 15393 times. Experts said that according to the current research data, the drug's ability to inhibit novel coronavirus ranked high among all novel coronavirus inhibitors found in humans.
(from January 2020, Professor Tong Yigang (middle) organized a team to tackle the key problems of Xinguan science and technology. Beijing University of Chemical Technology (website map)
On the 14th, tongyigang of Beijing University of chemical technology, the discoverer of the new crown treatment drug, posted a document on the social platform. He said that stephanine was an anti crown drug screened by the laboratory after the COVID-19 in February 2020. At that time, due to the sudden outbreak of the epidemic, the research and development of a new drug often took more than ten years. In order to speed up this process, they used some drugs already on the market to screen with virus culture models. Thousands of drugs were screened, and finally several effective drugs were obtained, among which the most effective was stephanine.
"Later, stephanine was also proved to be very effective for Xinguan by laboratories in many countries. Our article was published online on March 1, but the paper version of the magazine was published on May 5, so the publication date of our article was marked as May 5. After our article was published online, a team in Japan, inspired by us, combined stephanine with other drugs, also proved that stephanine was effective for Xinguan It has good effect ". He wrote in the article.
He said that the most powerful evidence is a science article published by the Americans. Their research found that the effect of stephanine against novel coronavirus is better than that of other drugs. It is the most effective drug against novel coronavirus at the cellular level known so far. A Canadian company has registered a clinical trial with the FDA and is expected to carry out a clinical trial of stephanine in the treatment of Xinguan in the second half of this year.
At the end of the article, he said, "because China does not have this drug on the market, it will take some time for China to carry out the research and development of this drug to go to the clinic and market.".
According to the jiupai news video report, Professor Tong Yigang said: the drug is still in preclinical state, and the patent of their team can ensure the application of the new drug in China. He also said that the drug is very promising and is very effective against variants such as Omicron. As for when the drug will be on the market, Professor Tong Yigang said that the drug will have "eyebrows and eyes" in 2023.